KEYNOTE-942

Event

Phase 2b clinical trial of mRNA-4157 plus pembrolizumab in resected melanoma

2 stories

Personalized Cancer Vaccine Shows Sustained Survival Benefit Six Years After Treatment

Cancer Researchers Report Encouraging Early Results for mRNA Vaccine Therapies